C4 Therapeutics, Inc. (CCCC) is a publicly traded Healthcare sector company. As of November 13, 2026, CCCC trades at $2.77 with a market cap of $363.75M and a P/E ratio of -3.14. CCCC moved -0.36% today. Year to date, CCCC is +36.21%; over the trailing twelve months it is +12.86%. Its 52-week range spans $1.09 to $5.17. Analyst consensus is strong buy with an average price target of $8.80. Rallies surfaces CCCC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
C4 Therapeutics Q3 loss per share beats estimates as costs fall: C4 Therapeutics reported a third-quarter loss of $0.16 per share, below the $0.20 estimate, and revenue of $8.50 million, slightly below estimates. Cash is expected to fund operations through the end of 2028; the company remains on track to complete MOMENTUM enrollment in the first quarter of 2027.
| Metric | Value |
|---|---|
| Price | $2.77 |
| Market Cap | $363.75M |
| P/E Ratio | -3.14 |
| EPS | $-0.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.17 |
| 52-Week Low | $1.09 |
| Volume | 2.38M |
| Avg Volume | 0 |
| Revenue (TTM) | $35.04M |
| Net Income | $-101.42M |
| Gross Margin | 0.00% |
6 analysts cover CCCC: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.80.